Micrus Corp.

Micrus hopes to break into the underpenetrated market of minimally invasive treatments for cerebral aneurysms with a microcoil that has, it claims, performance characteristics that are superior to Target Therapeutics' Guglielmi Detachable Coil.

Acute stroke represents a virtually unmet clinical need and a tremendous market opportunity. In the US, about 700,000 strokes occur each year, 80% of which are due to occluded vessels (ischemic stroke); the rest are caused by ruptured arteries leading to or within the brain (hemorrhagic stroke). While dozens of start-up companies are staking out claims in the unknown territory of ischemic stroke, Micrus Corp. deliberately sought out technology to treat the cerebral aneurysms and arteriovenous malformations that can cause hemorrhagic stroke. The company hopes to broaden a market created by Target Therapeutics Inc. (now part of Boston Scientific Inc.) with its Guglielmi DetachableCoil, the only FDA approved device for the minimally-invasive treatment of aneurysms. Although it is the only minimally invasive alternative, the GDC is still only used in 5% of patients; the open craniotomy and surgical clipping are still the gold standard for treating cerebral aneurysms. Micrus hopes to break into this existing but underpenetrated market with a new microcoil that has, it claims, performance characteristics that are superior to the GDC.

The goal of these devices is to fill and block an aneurysm, a balloon-like enlargement in a weak vessel wall,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.